PGNX - Progenics Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.3100
+0.0700 (+1.65%)
At close: 4:00PM EDT

4.3100 0.00 (0.00%)
After hours: 4:01PM EDT

Stock chart is not supported by your current browser
Previous close4.2400
Open4.3000
Bid4.3100 x 4000
Ask4.3900 x 1400
Day's range4.1800 - 4.3800
52-week range1.8900 - 6.3700
Volume432,278
Avg. volume892,331
Market cap373.231M
Beta (5Y monthly)1.88
PE ratio (TTM)N/A
EPS (TTM)-0.7740
Earnings date07 May 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.75
  • GlobeNewswire

    Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that the results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyLTM (18F-DCFPyL) in men with biochemical recurrence of prostate cancer will be presented in an oral session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program. PyL is the Company’s PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer.

  • GlobeNewswire

    Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

    Progenics Pharmaceuticals, Inc. (PGNX) today announced financial results for the first quarter 2020. “Progenics’ Board of Directors continues to believe the proposed merger with Lantheus under the revised terms is the best pathway forward to maximize shareholder value and escalate the advancement of its portfolio of radiopharmaceuticals for the detection and treatment of cancer,” said David Mims, Interim Chief Executive Officer of Progenics.

  • GlobeNewswire

    Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call and webcast to review first quarter ended March 31, 2020 financial results on Thursday, May 7, 2020, at 8:30 a.m. ET. A live webcast will be available in the Media Center of the Progenics website, www.progenics.com, and a replay will be available there for two weeks. Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imaging agents for prostate cancer (PyL™ and 1404); and imaging analysis technology (aBSI and PSMA AI).

  • ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics
    Business Wire

    ADDING MULTIMEDIA Velan Capital Agrees to Support Merger of Lantheus and Progenics

    Lantheus Holdings, Inc. (NASDAQ: LNTH) ("Lantheus"), parent company of Lantheus Medical Imaging, Inc. ("LMI"), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) ("Progenics"), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow cancer, today announced that Lantheus has entered into a Support Agreement (the "Support Agreement") with Velan Capital ("Velan") in connection with the proposed merger of Lantheus and Progenics.

  • GlobeNewswire

    PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS

    NEW YORK, March 13, 2020 -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. “The recent positive.

  • GlobeNewswire

    Progenics Pharmaceuticals Announces Presentations at the 2020 American Society of Clinical Oncology Genitourinary Cancers Symposium Annual Meeting (ASCO GU)

    NEW YORK, Feb. 06, 2020 -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find,.

  • GlobeNewswire

    Progenics Pharmaceuticals Provides Update on Reconstituted Board’s Ongoing Strategic Review

    On behalf of the Board of Directors, we are pleased to provide you with this update on our activities since you elected five new independent directors to the Company’s Board. With your clear mandate, we immediately took action to independently evaluate the business and prospects of Progenics, including the transaction with Lantheus Holdings, Inc. and to ensure that there is no interruption in the execution of the Company’s mission of developing and marketing products that improve outcomes for patients with cancer. In recent weeks, the Progenics Board and management team have been conducting two separate reviews in parallel to evaluate the proposed Lantheus transaction as well as Progenics’ business operations and standalone prospects in the event the Lantheus transaction is not consummated.

  • GlobeNewswire

    Progenics Pharmaceuticals Announces Presentation at the 2020 SNMMI Mid-Winter Meeting

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting data from its PSMA AI program has been selected for a moderated poster presentation at the 2020 Society for Nuclear and Molecular Medicine (SNMMI) Mid-Winter Meeting, which will be held from January 23 – 25, 2020 in Tampa, FL. PyL (also known as 18F-DCFPyL) is a fluorinated PSMA-targeted positron emission tomography (“PET”) imaging agent that enables visualization of both bone and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer.

  • GlobeNewswire

    Progenics Pharmaceuticals Announces Phase 3 CONDOR Trial of PyL™ in Prostate Cancer Achieved Primary Endpoint

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced positive top line results from the Phase 3 CONDOR trial evaluating the diagnostic performance and clinical impact of PyL™ (18F-DCFPyL) in men with biochemical recurrence of prostate cancer. PyL is the Company’s PSMA-targeted small molecule positron emission tomography (PET) imaging agent designed to visualize prostate cancer.

  • GlobeNewswire

    Progenics Pharmaceuticals to Announce and Host a Conference Call to Discuss Top Line Results from Phase 3 CONDOR Trial of PyL™ in Prostate Cancer on Monday, December 23rd

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call to review the top line results from the Phase 3 CONDOR trial of PyL™ (18F-DCFPyL) in men with biochemical recurrence of prostate cancer on Monday, December 23, 2019, at 8:00 a.m. ET. The Company intends to issue a press release announcing the top line results of the CONDOR trial on the same day in advance of the conference call. Progenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen (“PSMA”) targeted imaging agents for prostate cancer (PyL™ and 1404); and imaging analysis technology (aBSI and PSMA AI).

  • GlobeNewswire

    SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of the Following Mergers

    WILMINGTON, Del., Dec. 12, 2019 -- Rigrodsky & Long, P.A. announces that it is investigating: Progenics Pharmaceuticals, Inc. (NASDAQ GS: PGNX) regarding possible.

  • GlobeNewswire

    SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AXE, CISN, IPHS, PGNX

    NEW YORK, Dec. 10, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Anixter International Inc. (NYSE: AXE) The.

  • GlobeNewswire

    INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders – AMTD, TIF, MDCO, PGNX

    NEW YORK, Dec. 04, 2019 -- Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: TD Ameritrade Holding Corporation (NASDAQ:.

  • GlobeNewswire

    Progenics Pharmaceuticals Announces Presentations at the Radiological Society of North America (RSNA) Annual Meeting

    NEW YORK, Nov. 25, 2019 -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find,.

  • GlobeNewswire

    Progenics Pharmaceuticals Appoints David Mims as Interim Chief Executive Officer

    Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced its Board of Directors has appointed David W. Mims as interim Chief Executive Officer. Mr. Mims, a member of Progenics’ Board of Directors, will assume the leadership of the executive team while the Board of Directors conducts a search to identify a permanent Chief Executive Officer. “David is a veteran pharmaceutical executive with deep experience leading multiple commercial organizations, including growing Aptalis Pharma to $475 million in annual net sales in the U.S.,” said Ann MacDougall, Interim Chair of the Board.

  • GlobeNewswire

    Progenics Pharmaceuticals Announces Delivery of Consents and Revocations to Independent Inspector of Elections

    Progenics Pharmaceuticals, Inc. (PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has delivered all consents and revocations that it has received to its independent inspector of elections in connection with the previously announced consent solicitation by Velan Capital L.P.’s (“Velan”) seeking to reconstitute the Progenics Board of Directors through the removal of three directors and the election of its five nominees and certain other proposals. Upon receipt of a preliminary count from the independent inspector, Progenics and Velan will each have an opportunity to review and challenge the validity of the consents and revocations received.

  • Progenics (PGNX) Reports Q3 Loss, Lags Revenue Estimates
    Zacks

    Progenics (PGNX) Reports Q3 Loss, Lags Revenue Estimates

    Progenics (PGNX) delivered earnings and revenue surprises of 18.52% and -20.35%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Analysts Estimate Progenics (PGNX) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Progenics (PGNX) to Report a Decline in Earnings: What to Look Out for

    Progenics (PGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire

    Progenics Pharmaceuticals Announces Business Update And Third Quarter 2019 Financial Results

    Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical.

  • GlobeNewswire

    Progenics Reminds Shareholders that November 17 is the True Deadline for Velan’s Consent Solicitation

    Progenics Pharmaceuticals, Inc. (PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the following statement clarifying November 17, 2019 as the true deadline for Velan Capital L.P.’s (“Velan”) consent solicitation. The true deadline for the Velan consent solicitation is November 17, 2019, not the November 8, 2019 “goal¹” arbitrarily set by Velan to try and force shareholders to vote without complete information.

  • GlobeNewswire

    Progenics Urges Shareholders to Reject the Risk and Uncertainty That Would be Caused by Giving Velan’s Nominees Control of the Board

    Progenics Pharmaceuticals, Inc. (PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the following letter that it intends to mail to shareholders, urging shareholders to revoke any consents previously delivered to Velan Capital L.P. (“Velan”) by signing and returning Progenics’ WHITE Consent Revocation Card. Velan Capital, L.P. (“Velan”) is attempting to take control of Progenics by replacing five of the seven directors on the Board of Directors through a consent solicitation campaign.

  • GlobeNewswire

    Progenics Reminds Shareholders that November 17 is the Only Deadline for Velan’s Consent Solicitation

    Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 Shareholders Should Ignore Any Earlier.

  • GlobeNewswire

    Progenics Strongly Agrees With ISS Recommendation that Velan Group SHOULD NOT Get Majority Control of the Board of Directors

    ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders.

  • GlobeNewswire

    Progenics Highlights Additional Serious Concerns About Velan Capital, L.P.

    Progenics Pharmaceuticals, Inc. (PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today issued the following letter that it intends to mail to shareholders, highlighting Velan Capital L.P.’s (“Velan”) knowledge of the Company’s proposed transaction with Lantheus Holdings, Inc. (LNTH) (“Lantheus”) weeks before it was made public, which raises significant concerns about Velan’s questionable securities trading, governance and ethical practices. Additionally, Progenics urges Velan’s five nominees to consider if they want to risk their reputations and continue to be associated with someone that operates in Velan’s manner.